item management s discussion and analysis of financial condition and results of operations overview the following management s discussion and analysis is based on historical financial results of pharmacopeia  inc pharmacopeia or the company and includes certain forward looking statements that do not specifically reflect the impact that the proposed merger described below under the caption proposed merger may have on future financial performance of the post merger company 
such performance may not follow the same historical trends as those presented in the following discussion 
pharmacopeia was incorporated in march and is engaged in research and development and chemical library production for collaborations and for its own use 
the company s research and development has focused on efficient  cost effective  high throughput systems for synthesizing and screening large libraries of chemicals for new drug discovery and optimization 
the company has incurred losses since inception and  as of december  had an accumulated deficit of million 
the company anticipates incurring additional losses over at least the next several years as it expands its research and development and chemical library production efforts 
the company expects that its losses will fluctuate from quarter to quarter and that such variations may be substantial 
results of operations the company expects that its revenue sources for at least the next several years will be limited to future drug discovery collaboration payments from schering plough  berlex  novartis  bayer  daiichi  organon  zeneca and bms and from other customers under existing arrangements and others that may be entered into in the future 
the timing and amounts of such revenues  if any  will likely fluctuate 
historical results should not be viewed as indicative of future operating results 
the company will be required to conduct significant research  development and production activities during the next several years to fulfill its obligations under its drug discovery collaborative agreements and to develop other collaborations and technologies 
the company does not anticipate having net income in the next several years 
years ended december  and revenues increased to million in  compared to million in the increase of million in revenues is primarily the result of the company s new collaboration with bms and its expanded efforts in the drug discovery collaborations with bayer  daiichi  and organon 
the company s source of revenues for the next several years will be interest income  payments under its current collaborations and payments from other customers  to the extent that the company enters into any additional arrangements 
research and development expenses increased to million compared to million in these increased amounts primarily reflect increased salaries  personnel and facilities lease expenses as the company continued to hire additional research and development personnel  equipment depreciation  leasehold amortization  and laboratory supplies purchased in connection with the expansion of the company s chemical library production and screening efforts for drug discovery collaborations and for internal discovery programs 
research and development expenses are expected to continue to increase as the company further expands its activities and incurs  among other things  expenses related to additional staff increases  increased rent for expanded facilities  and increased equipment and reagent purchases 
general and administrative expenses were million and million in the years ended december  and  respectively 
the increase is primarily attributable to increased payroll and personnel expenses as the company continued to hire additional management and administrative personnel  along with increased patent legal fees 
the company had interest income of million in compared to million in the increase in interest income resulted from higher average balances of cash  cash equivalents and marketable securities 
interest expense for both periods is a result of interest incurred on notes payable 
years ended december  and revenues increased to million in  compared to million in the increase of million primarily reflected expanded efforts in the company s collaborations with schering plough  berlex  novartis  bayer  daiichi and nv organon 
the revenues were attributable entirely to the schering plough and berlex collaborations 
the company incurred research and development expenses of million and million in the years ended december  and  respectively 
these increased amounts primarily reflected increased salaries and personnel expenses as the company continued to hire additional research and development personnel  equipment depreciation and facilities expenses and laboratory supplies purchased in connection with the expansion of the company s chemical library production and screening efforts for collaborations and for its own use 
general and administrative expenses were million and million in the years ended december  and  respectively 
the increase was primarily attributable to increased payroll and personnel expenses as the company hired additional management and administrative personnel and incurred additional legal  insurance and other professional fees in connection with the overall scale up of the company s operations 
liquidity and capital resources as of december   the company had working capital of million 
the company has funded its activities through december  primarily through the sale of equity securities and funding under collaborative arrangements 
from inception through december   the company received million in net proceeds from equity financing and received million in research and development  license fees and milestone payments under collaborative agreements 
the company s funds are currently invested in us treasury and government agency obligations  investment grade commercial paper and other short term money market instruments 
the company may also invest such proceeds in investment grade  interest bearing securities having a maximum maturity of two years 
as of december   the company s cash and cash equivalents totaled million 
in addition  the company had marketable securities of million 
see note to financial statements 
in connection with the company s agreement with the trustees of columbia university and cold spring harbor laboratory  the company is required to pay annual license fees 
the company is also required to pay to columbia university certain royalties 
in addition  as of december   the company had outstanding commitments for construction and equipment purchases totaling million 
the company anticipates that its capital requirements will continue at approximately the same level over the next two years as the company expands its research and development activities 
in connection with such expansion  the company expects to incur substantial expenditures for hiring additional management  scientific and administrative personnel and for planned expansion and upgrading of its facilities  including acquisition of additional equipment 
as of december   the company had federal net operating loss carryforwards of million 
these carryforwards will expire beginning in the year utilization of the net operating loss carryforwards will be subject to limitation under section of the internal revenue code 
see note of notes to financial statements 
the company anticipates that its existing capital resources will be adequate to fund the company s operations at least through there can be no assurance that changes will not occur that would consume available capital resources before such time 
the company s capital requirements depend on numerous factors  including the ability of the company to extend existing collaborations and enter into additional collaborative arrangements  competing technological and market developments  changes in the company s existing collaborative relationships  the cost of filing  prosecuting  defending and enforcing patent claims and other intellectual property rights and the outcome of related litigation  the purchase of additional capital equipment  acquisitions of other businesses or technologies  the progress of the company s drug discovery programs and the progress of the company s customers milestone and royalty producing activities 
there can be no assurance that additional funding  if necessary  will be available on favorable terms  if at all 
the company s forecasts of the period of time through which its financial resources will be adequate to support its operations is forward looking information  and actual results could vary 
the factors described earlier in this paragraph will impact the company s future capital requirements and the adequacy of its available funds 
based on preliminary reviews  the company believes that its significant internal computer information systems are year compliant 
all other internal systems are currently being assessed and a further review of all systems is currently planned 
given the information known at this time  the company does not believe that changes to its systems to make them year compliant will require significant resources or material costs 
no assurance can be given  however  that all of the company s systems will be year compliant on a timely basis or that actual compliance costs or the impact of the company s failure to achieve substantial year compliance will not have a material adverse effect on the company 
the company intends to contact its significant suppliers and large customers to determine the extent to which the company is vulnerable to those third parties failure to remediate their own year issue 
to date  the company is unaware of any situations of noncompliance that would adversely affect its operations 
however  there can be no assurance that the systems of other companies on which the company s systems rely will be timely converted or that a failure to convert by another company would not have a material adverse effect on the company 
proposed merger on february   pharmacopeia  micro acquisition corporation  a wholly owned subsidiary of pharmacopeia mac and molecular simulations incorporated msi executed a definitive merger agreement the merger agreement pursuant to which pharmacopeia will acquire msi in a tax free  stock for stock transaction  which pharmacopeia expects will qualify for accounting treatment on a pooling of interests basis 
pursuant to the merger agreement  mac will be merged into msi with msi as the surviving corporation 
assuming that outstanding options to purchase shares of common stock of msi are not exercised before the effective time of the merger  pharmacopeia will a acquire all of the outstanding capital stock of msi in exchange for approximately million newly issued shares of pharmacopeia common stock and b assume the outstanding msi options  which will then be exercisable for shares of pharmacopeia common stock  potentially resulting in the issuance of up to an additional million newly issued shares of pharmacopeia common stock 
the transaction is subject to certain conditions  including stockholder approvals  the effectiveness of a registration statement under federal securities laws relating to the pharmacopeia common stock to be issued in the merger  the listing of such pharmacopeia common stock on the nasdaq national market and the expiration of applicable waiting periods under pre merger notification regulations 
as of december  msi had total assets of million and for the year ended december  msi had total revenue of million and net income of million 
after the closing of the merger  pharmacopeia will file  as part of a current report on form k  unaudited pro forma combined condensed financial statements that give effect to the merger 
item a 
quantitative and qualitative disclosures about market risk not applicable 

